Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 30:11:1367442.
doi: 10.3389/fcvm.2024.1367442. eCollection 2024.

The role of tolvaptan add-on therapy in patients with acute heart failure: a systematic review and network meta-analysis

Vireza Pratama  1   2   3 , Jordan Budiono  4 , Jarir At Thobari  5   6 , Bambang Widyantoro  7 , Vita Yanti Anggraeni  8 , Lucia Kris Dinarti  9
Affiliations

The role of tolvaptan add-on therapy in patients with acute heart failure: a systematic review and network meta-analysis

Vireza Pratama et al. Front Cardiovasc Med. .

Abstract

Background: Several conflicting reviews have concluded that the use of loop diuretics is associated with poorer clinical and safety outcomes. Therefore, this study aimed to investigate the efficacy and safety of tolvaptan as an adjunct to conventional diuretic therapy in patients with acute heart failure (AHF).

Methods: A comprehensive search was conducted on PubMed, Embase, ProQuest, EBSCO, and Cochrane Library until 24 May 2023 to identify randomized controlled trials that compared the effects of tolvaptan with conventional therapy and placebo in patients with AHF. The quality assessment of the included trials was conducted using the Cochrane risk of bias. A network meta-analysis (NMA) was conducted to examine the dosage effect of tolvaptan.

Result: A total of 17 studies with 18 reports, involving 10,039 patients, were selected. The tolvaptan add-on therapy significantly alleviated dyspnea [24 h: RR 1.16 (1.04, 1.29), 48 h: RR 1.18 (1.04, 1.33)], reduced body weight within 48 h [Asian group, MD -0.93 (-1.48, -0.38); non-Asian group, MD -2.76 (-2.88, -2.65)], reduced edema [RR 1.08 (1.02, 1.15)], increased serum sodium [non-Asian group, MD 3.40 (3.02, 3.78)], and resulted in a change in serum creatinine [MD -0.10 (-0.18, -0.01)]. No significant differences were observed in mortality and rehospitalization. The NMA suggested that an intermediate dosage (15 mg/day) might offer the best efficacy in reducing dyspnea within 24 h, reducing edema, increasing serum sodium, and lowering the incidence of worsening renal function (WRF).

Conclusion: In conclusion, the meta-analysis showed that tolvaptan contributed to the short-term alleviation of congestive symptoms, elevated sodium levels, and a lower incidence of WRF. However, no significant benefits were observed in long-term symptoms, rehospitalization rates, and mortality. An intermediate dosage of tolvaptan might be considered the optimal choice for various clinical outcomes.

Systematic review registration: https://www.crd.york.ac.uk/, PROSPERO (CRD42023420288).

Keywords: acute heart failure; heart failure; network meta-analysis; systematic review; tolvaptan.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flowchart showing the eligibility of studies for inclusion in the updated meta-analysis.
Figure 2
Figure 2
Forest plot depicting the effects of add-on tolvaptan on clinical outcomes. The effects of add-on tolvaptan on dyspnea relief within 24 h (A), dyspnea relief within 48 h (B), changes in body weight within 48 h (C), changes in body weight within 7 days (D), edema reduction (E), changes in serum sodium (F) and creatinine (G) levels, mortality (H), and rehospitalization (I).
Figure 3
Figure 3
Network meta-analysis (NMA) on the tolvaptan dosage effect subgroup analysis. Contrast plot showing the dosage effect of each efficacy and safety indicator. (A) Network analysis contrast plot of dyspnea within 24 h; (B) network analysis contrast plot of dyspnea within ≥48 h; (C) network analysis contrast plot of reduced body weight within 48 h; (D) network analysis contrast plot of reduced body weight within 7 days; (E) network analysis contrast plot of edema; (F) network analysis contrast plot of serum sodium level; (G) network analysis contrast plot of serum creatinine level; and (H) network analysis contrast plot of mortality.
Figure 4
Figure 4
Contour-enhanced funnel plot and heat map for each efficacy and safety indicator.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Javaloyes P, Miró Ò, Gil V, Martín-Sánchez FJ, Jacob J, Herrero P, et al. Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes. Eur J Heart Fail. (2019) 21(11):1353–65. 10.1002/ejhf.1502 - DOI - PubMed
    1. Simonavičius J, Knackstedt C, Brunner-La Rocca H-P. Loop diuretics in chronic heart failure: how to manage congestion? Heart Fail Rev. (2019) 24(1):17–30. 10.1007/s10741-018-9735-7 - DOI - PubMed
    1. Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, et al. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction. J Card Fail. (2016) 22(6):423–32. 10.1016/j.cardfail.2016.02.007 - DOI - PubMed
    1. Kansara T, Gandhi H, Majmundar M, Kumar A, Patel JA, Kokkirala A, et al. Tolvaptan add-on therapy and its effects on efficacy parameters and outcomes in patients hospitalized with heart failure. Indian Heart J. (2022) 74(1):40–4. 10.1016/j.ihj.2021.12.003 - DOI - PMC - PubMed
    1. Lin YH, Tsai CH, Chiang CE, Kuo JY, Yin WH, Wen MS, et al. The efficacy and safety of short-term tolvaptan usage in patients with acute decompensated heart failure. Acta Cardiol Sin. (2022) 38(6):700–13. 10.6515/ACS.202211_38(6).20220422A - DOI - PMC - PubMed

Publication types

LinkOut - more resources